Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration (FDA).
Men's Health Network (MHN) is excited to see this innovative treatment option made available for patients with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer. Provenge harnesses the individual's own immune system to fight cancer through a process called active cellular immunotherapy.
Provenge offers hope for men (and their families) to potentially extend and improve the quality of life for those who are suffering from advanced prostate cancer. Patients should work with their healthcare providers to determine if they are an appropriate candidate for Provenge at this time.
There is an immense need for more options and awareness about the plight of men with advanced prostate cancer. MHN is very excited that the approval of Provenge brings us one step closer to this goal by adding a breakthrough treatment option for these men. Men now have an opportunity to engage in a conversation with their health care provider about this new innovative immunotherapy to potentially extend and improve their quality of life.
Mursla Bio announces promising results for EvoLiver test in liver cancer detection